Beigene Ltd (BGNE) Expected to Announce Earnings of -$1.74 Per Share

Equities research analysts predict that Beigene Ltd (NASDAQ:BGNE) will announce earnings per share (EPS) of ($1.74) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Beigene’s earnings, with the highest EPS estimate coming in at ($1.41) and the lowest estimate coming in at ($1.94). Beigene reported earnings per share of ($1.05) during the same quarter last year, which would suggest a negative year-over-year growth rate of 65.7%. The company is scheduled to report its next earnings results on Wednesday, March 28th.

According to Zacks, analysts expect that Beigene will report full-year earnings of ($2.04) per share for the current fiscal year, with EPS estimates ranging from ($2.49) to ($1.59). For the next year, analysts expect that the business will report earnings of ($7.56) per share, with EPS estimates ranging from ($9.25) to ($5.88). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Beigene.

Beigene (NASDAQ:BGNE) last announced its quarterly earnings results on Monday, November 13th. The company reported $2.54 EPS for the quarter, topping the consensus estimate of $0.23 by $2.31. The company had revenue of $220.21 million during the quarter, compared to analysts’ expectations of $1.55 million. During the same quarter in the previous year, the firm earned ($1.08) EPS.

Several analysts have commented on the stock. Zacks Investment Research cut shares of Beigene from a “hold” rating to a “sell” rating in a research note on Monday. Cowen reiterated a “buy” rating on shares of Beigene in a research note on Monday. BidaskClub upgraded shares of Beigene from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Maxim Group set a $120.00 price target on shares of Beigene and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. Finally, ValuEngine cut shares of Beigene from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. Beigene has an average rating of “Buy” and an average price target of $96.67.

In other news, CMO Amy C. Peterson sold 3,601 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $82.96, for a total transaction of $298,738.96. Following the sale, the chief marketing officer now directly owns 1,201 shares in the company, valued at approximately $99,634.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John Oyler sold 150,957 shares of the stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $80.50, for a total transaction of $12,152,038.50. Following the completion of the sale, the chief executive officer now directly owns 491,891 shares in the company, valued at $39,597,225.50. The disclosure for this sale can be found here. Insiders have sold a total of 483,482 shares of company stock worth $42,139,474 over the last 90 days. Corporate insiders own 19.90% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. Hillhouse Capital Management Ltd. raised its position in Beigene by 172.6% in the 2nd quarter. Hillhouse Capital Management Ltd. now owns 3,720,726 shares of the company’s stock worth $167,433,000 after purchasing an additional 2,355,906 shares during the period. Orbimed Advisors LLC raised its position in Beigene by 2.0% in the 3rd quarter. Orbimed Advisors LLC now owns 1,313,788 shares of the company’s stock worth $135,925,000 after purchasing an additional 26,200 shares during the period. Canada Pension Plan Investment Board purchased a new stake in Beigene in the 3rd quarter worth about $62,076,000. Artal Group S.A. raised its position in Beigene by 10.1% in the 2nd quarter. Artal Group S.A. now owns 400,000 shares of the company’s stock worth $18,000,000 after purchasing an additional 36,714 shares during the period. Finally, Janus Henderson Group PLC purchased a new stake in Beigene in the 3rd quarter worth about $33,744,000. 55.32% of the stock is currently owned by institutional investors.

Shares of Beigene (BGNE) traded up $1.34 during mid-day trading on Friday, reaching $101.67. 220,200 shares of the company’s stock traded hands, compared to its average volume of 189,700. The stock has a market cap of $4,620.00 and a PE ratio of -77.61. Beigene has a 1-year low of $30.67 and a 1-year high of $118.95. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.27 and a current ratio of 9.33.

TRADEMARK VIOLATION WARNING: “Beigene Ltd (BGNE) Expected to Announce Earnings of -$1.74 Per Share” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.com-unik.info/2018/01/10/beigene-ltd-bgne-expected-to-announce-earnings-of-1-74-per-share.html.

Beigene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Get a free copy of the Zacks research report on Beigene (BGNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit